# AZD4045

Source: https://onco.cc/drugs/azd4045/  
OnCo record `azd4045` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD4045 is an experimental CAR-T cell therapy from AstraZeneca in phase 2 trials for multiple myeloma, aimed at BCMA.

## Summary

AZD4045 is a CAR-T cell therapy developed by AstraZeneca. Its target is BCMA (the sponsor names BCMA). The sponsor states: An allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA). ClinicalTrials.gov describes the intervention as: Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT07681596, plans to enrol 101 participants with primary completion expected 2031-03-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: An allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA).

## Sources

- ClinicalTrials.gov: trials of AZD4045: https://clinicaltrials.gov/search?intr=AZD4045

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct07681596/)

---
JSON: https://onco.cc/api/v1/entities/azd4045.json